Table 5.
Identified significant molecular pathways associated with the comorbidities.
| Database | Molecular pathway | P value | Genes in the pathway | Associated comorbidity |
|---|---|---|---|---|
| WikiPathway | Immune system | 7.80E − 05 | ZBP1; DUSP5; GBP5; RASGRF2; IL1R2; HLA-B; LIF; FN1; ISG15; HLA-A; HLA-F; HLA-G; OASL; C3; IL1B; IRF7; HLA-DRA | Hypertension |
| Reactome | Interferon gamma signaling | 2.89E − 09 | GBP5; HLA-B; IRF7; HLA-DRA; HLA-A; HLA-F; HLA-G; OASL | Hypertension |
| Reactome | T cell receptor signaling | 3.26E − 02 | HLA-DRA; PSMB9 | Diabetes |
| KEGG | Apoptosis | 4.57E − 02 | DAXX; LMNB1 | Diabetes |
| KEGG | Tryptophan metabolism | 3.13E − 04 | IL4I1; KYNU; KMO | Obesity |
| KEGG | Glycolysis/gluconeogenesis | 1.24E − 03 | LDHC; ADH1A; ALDOB | Obesity |
| WikiPathway | Matrix metalloproteinases | 1.14E − 04 | MMP7; MMP8; MMP9 | Obesity |
| KEGG | Cytokine-cytokine receptor interaction | 2.01E − 02 | IL1A; IL33; CXCL11; IL16; LTB; IL6R | Lung cancer |
| KEEG | ECM-receptor interaction | 4.38E − 04 | VWF; SV2B; ITGA10; CD36; NPNT | Lung cancer |
| KEEG | Protein digestion and absorption | 6.57E − 03 | COL5A3; COL22A1; COL11A2; SLC8A2 | Lung cancer |